Enzymotec has announced that it has received the Japanese patent office's approval for production process of Lyso-Phospholipids. The patent, entitled “enzymatic process for the production of predetermined 1-acyl-2 lyso and 1,2-diacylated glycerophospholipids and their synthetic or natural analogues” (JP 4216082), was granted on 14.11.08 following approvals from the Israel and US patent offices. The glycerophospholipids referred to in the patent include; phosphatidyl choline, phosphatidyl ethanol amine, phosphatidyl serine , phosphatidylinositol and phosphatidylglycerol.
Enzymotec continues to invest efforts in order to expand its variety of products, especially the phospholipids based ones.
Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional solutions for orthomolecular medicine, dietary supplements and advanced infant nutrition. Key products are: Sharp-PS® line of products- phosphatidylserine based ingredients for cognitive improvement, InFat® - structured fat for infant formulas, CardiaBeat® offering a broad health effect to reduce CVD risks and Krill Oil+™.